Study achieved median overall survival of 31.7 months Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form Pleasanton, CA, September 23, 2021. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka […]
About Peggy Bickerton
This author has not written his bio yet.
But we are proud to say that Peggy Bickerton contributed 56 entries already.
Entries by Peggy Bickerton
EHA Congress of the European Hematology Association 9 – 17 June 2021 Virtual Event visit conference website
ASCO Annual Meeting 4 – 8 June 2021 Virtual Event visit conference website
AACR Annual Meeting Week 2: 17-21 May Virtual Event visit conference website
For Immediate Release: April 14, 2021Media Contact:Rachel Darwin267firstname.lastname@example.org NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes. PLYMOUTH MEETING, PA [April 14, 2021] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and […]
The Acute Leukemia Forum (ALF) 7 – 8 April 2021 Virtual Event visit conference website
ESH: 7th Translational Research Conference: Myelodysplastic Syndromes (rescheduled from 23 – 25 April 2020) 28 – 31 January 2021 E-CONFERENCE visit conference website
ASH Annual Meeting 5 – 8 December 2020 Virtual Meeting visit conference website
32nd EORTC-NCI-AACR Symposium 24 – 25 October 2020 Virtual Meeting visit conference website
NCI has announced availability to investigators of oral decitabine and cedazuridine tablets for clinical and nonclinical study proposals under the CRADA The collaboration is intended to study oral decitabine and cedazuridine tablets in a range of tumor types Pleasanton, CA, – October 28th, 2020. – Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka […]